【Company Recommendation】Shanghai Wantewant Technology Co., Ltd

Company Profile We are a high-tech enterprise oriented towards research and development, specializing in the fields of pharmaceutical raw materials, intermediates, peptide components, cosmetic raw materials, and nutritional supplement raw materials. We offer standardized large-scale production services and conduct global wholesale business. Our multiple peptide raw materials possess core physiological effects such as weight loss, muscle building, blood sugar reduction, and anti-aging, are widely applicable to the research and production demands in the pharmaceutical, beauty, and health care sectors. We adopt strict batch production standards and have sufficient production capacity and stable supply capabilities. All products have been professionally tested by third-party institutions and come with complete test reports and qualification certificates, ensuring stable batch quality and complete traceability. For large-scale orders, we offer competitive wholesale prices. We uphold the core values of integrity, pragmatism, innovation and development, and continuously enhance our technical strength and product quality. Product Introduction We ...

• Source: drugdu
• 53
• July 10, 2026

Ascletis Pharma submits Investigational New Drug (IND) applications to the FDA for two new obesity drugs

Recently, Ascletis Pharma announced that it has recently submitted two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA): ASC36, a next-generation peptide amylin receptor agonist administered once monthly to quarterly, and ASC36_35FDC, a once-monthly injectable combination of ASC36 and the peptide GLP-1R/GIPR agonist ASC35, for the treatment of obesity. According to relevant data, the overweight rate among adults in my country is about 34.3%, and the obesity rate is about 16.4%; the overweight rate among children and adolescents aged 6 to 17 is 11.1%, and the obesity rate is 7.9%, indicating that the overall situation is still not optimistic. https://mp.weixin.qq.com/s/Vt-YLF5ncLZAxzwrngG75A

• Source: drugdu
• 55
• July 9, 2026

Fengtou News | Highlight Pharmaceuticals’ Ganoxitinib Receives Breakthrough Therapy Designation from CDE

Today, Glorious Pharmaceuticals announced that its independently developed oral highly selective JAK1/TYK2 dual inhibitor, ganoxitinib (TLL-018), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the treatment of rheumatoid arthritis (RA). This designation is based on positive topline data from the Ganoxitinib Phase III Registration Study (TARA). The CDE (Center for Drug Evaluation) has determined that Ganoxitinib meets the criteria for breakthrough therapy, indicating its use in the prevention and treatment of life-threatening or quality-of-life diseases, and demonstrating a more significant or important therapeutic effect compared to existing treatments. The TARA study is the world’s first Phase III clinical trial of RA using the marketed JAK inhibitor Shangjie® (tofacitinib) as a positive control and achieving the superiority endpoint. Data showed that ganoxitinib was significantly superior to tofacitinib in both the primary endpoint and all secondary efficacy endpoints (p ...

• Source: drugdu
• 56
• July 9, 2026

【Company Recommendation】Emeishan Hongsen Biopharmaceutical Co., Ltd.

Company Introduction Emeishan Hongsen Biopharmaceutical Co., Ltd. is a national high-tech enterprise focusing on peptide fragments, protected amino acids, pharmaceutical intermediates, APIs, and CMO/CDMO fields. Business scope: an experienced project undertaking team escorts full life-cycle CMO/CDMO services; a GMP quality system that has been audited many times by domestic and foreign customers; the company has an independent technology R&D center, a provincial enterprise technology center, and Leshan Synthetic Biology Engineering Technology Research Center, providing one-stop services including process optimization, R&D, production, and sales. The company was established on February 18, 2011. It currently has more than 150 employees and more than 70 sets of various reactors ranging from 100L to 6300L, providing flexible and diversified cooperation models. Star Products 89030-95-5 Copper Peptide Copper peptide can effectively stimulate the biosynthesis of collagen in fibroblasts, thereby promoting rapid wound healing. It can also effectively block the neurotransmission of acetylcholine substances, thereby relaxing ...

• Source: drugdu
• 91
• June 26, 2026

China’s first ADC (Advanced Dioxide Doppler) to be submitted for market approval

On June 23, the CDE (Center for Drug Evaluation) website showed that Chia Tai Tianqing Pharmaceutical Group’s application for marketing authorization of vetectobactimab for injection was accepted. This monotherapy is indicated for patients with CLDN18.2-positive, locally advanced, or metastatic gastric/gastroesophageal junction adenocarcinoma who have received at least two lines of prior systemic therapy . Previously, this drug had been formally included in the CDE’s priority review and approval process . Screenshot source: CDE official website Vitacotobactam (development code: LM-302 ) is an antibody-drug conjugate (ADC) targeting Claudin18.2 (CLDN18.2) developed by Lixin Pharmaceuticals. It specifically binds to CLDN18.2-positive tumor cells, enters the cells via endocytosis, and releases small molecule toxins to achieve precise killing of tumor cells. In July 2025, China Biopharmaceutical announced that it would acquire 100% of Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. for a net consideration of approximately US$500 million , bringing the latter’s highly regarded bispecific antibody ...

• Source: drugdu
• 93
• June 25, 2026

Sanofi’s second autoimmune BTK inhibitor approved for marketing

On June 23, Sanofi announced that Tolebrutinib (trade name: Cenrifki) has been approved by the European Medicines Agency (EMA) for the treatment of relapse-free secondary progressive multiple sclerosis (SPMS). This drug is the first approved treatment for non-relapsing SPMS and Sanofi’s second approved autoimmune BTK inhibitor. Sanofi’s first autoimmune BTK inhibitor, Rilzabrutinib (trade name: Wayrilz ), was approved in the US and Europe in 2025.This approval was supported by the Phase III HERCULES study , which included 1131 patients with non-recurrent SPMS .Patients. Results showed that at a median follow-up of 133 weeks, the proportion of patients in the Tolebrutinib (60 mg, once daily) group who had confirmeddisability progression lasting at least 6 months was significantly lower than that inthe placebo group (22.6% vs 30.7%, HR=0.69, P=0.003).Multiple sclerosis (MS) is a chronic, immune-mediated neurodegenerative disease of the central nervous system that can lead to persistent and irreversible disability over time. ...

• Source: drugdu
• 82
• June 25, 2026

Qingfeng Pharmaceutical’s apalutamide tablets have been approved, adding another powerful tool to the field of anti-tumor therapy

According to the official website of the National Medical Products Administration (NMPA), the generic apalutamide tablets submitted by Kerui Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for production on May 19 and are considered to have passed the consistency evaluation. This is the third endocrine therapy chemical drug approved for Qingfeng Pharmaceutical, marking a new milestone in the company’s R&D and commercialization strategy in the field of prostate cancer treatment. 0 1 Apalutamide tablets: A new generation of androgen receptor inhibitors Blockbuster drugs for prostate cancer treatment Apalutamide is a new generation of oral, highly selective nonsteroidal androgen receptor (AR) inhibitors. It competitively blocks androgen binding by binding to the intracellular ligand-binding domain of AR with high affinity, inhibiting receptor conformational changes and nuclear translocation, and preventing AR translocation into the nucleus.¹ Simultaneously, it blocks the binding of AR to DNA response elements, inhibiting the transcription ...

• Source: drugdu
• 85
• June 25, 2026

Three Conversations We Heard Repeatedly at CPHI China 2026

Three days at CPHI China 2026 gave us the opportunity to meet pharmaceutical manufacturers, suppliers, buyers, and industry professionals from around the world. For Drugdu.com, exhibitions are not only about networking. They are also one of the best places to observe how the pharmaceutical industry is evolving and what companies are focusing on next. After hundreds of conversations across APIs, formulations, extracts, excipients, and pharmaceutical services, a few themes kept coming up. 1. Companies Are Looking for Their Next Growth Market One topic appeared repeatedly throughout the exhibition: Where should we focus next? Latin America. The Middle East. Southeast Asia. These regions were mentioned far more often than we expected. Many companies are no longer asking whether they should expand internationally. They are already active in global markets. The discussion has shifted toward market selection, resource allocation, and identifying the next region that offers sustainable growth. For many pharmaceutical companies, ...

• Source: drugdu
• 84
• June 20, 2026

On June 16, foreign media suddenly reported several pieces of news about semaglutide. One was that Novo Nordisk’s oral weight-loss drug Wegovy would soon be launched in China; another was that Novo Nordisk made it clear: regulatory data protection for semaglutide in China will last until the second quarter of 2027, when generics will be able to enter the market. According to foreign media reports, both pieces of news came from Novo Nordisk’s Global President and CEO, Mike Doustdar. In the past few days, Novo Nordisk’s global management has happened to be visiting China. On June 15, Health News reported that Lei Haichao, Director of the National Health Commission, met with several Novo Nordisk executives, to discuss Novo Nordisk’s presence in China and its future strategy. The two major pieces of news above were very likely leaked during this public event, drawing strong market attention. The news about oral semaglutide ...

• Source: drugdu
• 94
• June 17, 2026

World’s first! CSPC Group’s paclitaxel for injection (albumin-bound) (II) approved for marketing

  On June 15, CSPC Group’s paclitaxel for injection (albumin-bound) (II) (R&D code: SYHX2011) was approved for marketing by the National Medical Products Administration. This product is the world’s first fast-dissolving albumin-bound paclitaxel formulation, backed by independently developed innovative formulation and manufacturing processes, and has obtained patent authorizations in multiple countries including China, the U.S., and Europe. As a Class 2.2 modified new chemical drug, it represents a comprehensive upgrade in efficacy, safety, and clinical convenience, filling many of the clinical gaps of conventional albumin-bound paclitaxel, marking CSPC Group’s technological breakthrough in the field of antitumor nanomedicines and offering a better chemotherapy option for patients with advanced breast cancer. Figure 1. CSPC paclitaxel for injection (albumin-bound) (II) approved for marketing, source: NMPA website 01Breast Cancer and Taxanes Breast cancer is a highly prevalent malignant tumor in China. According to a report by the National Cancer Center of China, there were ...

• Source: drugdu
• 107
• June 17, 2026